September 27, 2023
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
September 7, 2023
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
August 28, 2023
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
August 9, 2023
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 8, 2023
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
August 7, 2023
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
August 3, 2023
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
June 22, 2023
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
June 15, 2023
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
Displaying 1 - 10 of 21